Biotech Showcase™ 2017: Refocusing Tarveda on tumor-targeted mini-drug conjugates

January 19, 2017
In the past 18 months, Tarveda Therapeutics has been refocusing its efforts on Pentarins, its miniaturized drug conjugates, designed to target, penetrate and eradicate solid tumors. Having raised USD 38 million early in 2016 to execute the plan, Tarveda president, CEO and interim chairman, Drew Fromkin, explains to Mike Ward, Informa Pharma Intelligence insights global director of content, what progress has been made and what milestones are on the horizon.
Previous Video
Biotech Showcase™ 2017: AmpliPhi advances phage in clinic to address microbial infections
Biotech Showcase™ 2017: AmpliPhi advances phage in clinic to address microbial infections

Using cocktails of bacteriophages to attack bacterial infections, San Diego-based AmpliPhi announced progre...

Next Video
Biotech Showcase™ 2017: Shield pilots ironclad specialty future with Feraccru
Biotech Showcase™ 2017: Shield pilots ironclad specialty future with Feraccru

Bolstered with a successful launch in Germany and the UK of its anemia treatment Feraccru, Shield Therapeut...